Metsera shareholders vote for $10 billion acquisition by Pfizer

Core Insights - Metsera shareholders approved Pfizer's takeover offer valued at up to $10 billion, enabling Pfizer's re-entry into the obesity treatment market [1] Group 1: Company Actions - Pfizer's acquisition of Metsera marks a strategic move to re-enter the lucrative obesity treatment market [1] Group 2: Market Implications - The approval of the takeover reflects the competitive landscape in the obesity treatment sector, highlighting the potential for significant market opportunities [1]